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 Decreased systolic function is a central factor in HFrEF.
 Current and investigational inotropic calcitropic drugs have uniformly resulted in signals
of increased mortality.
 OM is a myotrope and a selective cardiac myosin activator that improves cardiac function.
 The GALACTIC-HF trial evaluates the effect of OM on outcomes in patients with chronic HF.ABSTRACTSA central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction is the initial decrease in systolic
function. Prior attempts at increasing cardiac contractility with oral drugs have uniformly resulted in signals of increased
mortality at pharmacologically effective doses. Omecamtiv mecarbil is a novel, selective cardiac myosin activator that has
been shown to improve cardiac function and to decrease ventricular volumes, heart rate, and N-terminal pro–B-type
natriuretic peptide in patients with chronic HF. The GALACTIC-HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure) trial tests the hypotheses that omecamtiv mecarbil can safely
improve symptoms, prevent clinical HF events, and delay CV death in patients with chronic HF. The GALACTIC-HF trial is
an international, multicenter, randomized, double-blind, placebo-controlled, event-driven cardiovascular outcomes trial.
More than 8,000 patients with chronic symptomatic (New York Heart Association functional class II to IV) HF, left
ventricular ejection fraction #35%, elevated natriuretic peptides, and either current hospitalization for HF or history of
hospitalization or emergency department visit for HF within a year of screening will be randomized to either oral placebo
or omecamtiv mecarbil employing a pharmacokinetic-guided dose titration strategy using doses of 25, 37.5, or 50 mg
twice daily. The primary efficacy outcome is the time to cardiovascular death or first HF event. The study has 90% power
to assess a final hazard ratio of approximately 0.80 in cardiovascular death, the first secondary outcome. The GALACTIC-
HF trial is the first trial examining whether selectively increasing cardiac contractility in patients with HF with
reduced ejection fraction will result in improved clinical outcomes. (Registrational Study With Omecamtiv Mecarbil/
AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329) (J Am Coll
Cardiol HF 2020;8:329–40) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2019.12.001
ABBR EV I A T I ON S
AND ACRONYMS
ATP = adenosine triphosphate
CI = confidence interval
CV = cardiovascular
ETT = exercise treadmill test
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular ejection
fraction
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
NYHA = New York Heart
Association
OM = omecamtiv mecarbil
PK = pharmacokinetic
SET = systolic ejection time
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330O f the millions of patients with heartfailure (HF) worldwide, at leastone-half have HF with reduced
ejection fraction (HFrEF). A central factor in
the pathogenesis of HFrEF is the initial
decrease in cardiac systolic function, yet for
more than a century scientists and physicians
have been unsuccessful in developing effec-
tive and safe oral therapies to directly
improve systolic function. Omecamtiv
mecarbil (OM) is a novel selective cardiac
myosin activator that improves cardiac func-
tion in patients with chronic HFrEF (1). The
GALACTIC-HF (Global Approach to Lowering
Adverse Cardiac outcomes Through
Improving Contractility in Heart Failure) trial
will test the hypothesis that OM can safely
improve clinical outcomes in patients with
HFrEF.HFrEF AND APPROACHES TO INCREASING
CARDIAC CONTRACTILITY
THERAPEUTIC HYPOTHESIS. HFrEF is an insidious
disorder resulting from loss or dysfunction of car-
diomyocytes (2). The consequent reduction in con-
tractile function and increase in cardiac wall stress
triggers multiple interrelated compensatory mecha-
nisms, including neurohormonal activation andSection of Cardiology, San Francisco Veterans Affairs Medical Cen
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results in increased myocardial oxygen demand and
reduced contractile efficiency, eventually promoting
additional myocardial injury and cardiomyocyte
death, perpetuating a negative feedback cycle that
results in symptomatic HF and eventually death.
Multiple life-saving therapies, including angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, mineralocorticoid antagonists, beta-
blockers, and most recently, angiotensin receptor-
neprilysin inhibitors, have been developed to
address the neurohormonal activation in HFrEF.
However, these therapies do not address the central
driver in the pathogenesis of HFrEF, the initial
decrease in systolic function. The hypothesis that
improving systolic function will prevent or attenuate
deleterious neurohormonal activation and ventricu-
lar remodeling, and consequently improve symptoms
and reduce the incidence of subsequent clinical
events such as HF hospitalizations and death has
been pursued since the discovery of epineph-
rine in 1895.
FAILURE OF INOTROPES THAT INCREASE INTRACELLULAR
CALCIUM (CALCITROPES). Many clinical programs have
developed oral inotropic drugs in chronic HFrEF, all
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TABLE 1 Clinical Trials With Oral Calcitropic Drugs in Chronic Heart Failure
Clinical Trial (Ref. #) Calcitrope Year N Key Inclusion Criteria Effects on Mortality
Xamoterol (Supplemental Ref. 1) Xamoterol 1990 516 LVEF <35%,
NYHA functional class III–IV
Xamoterol: 32 deaths/n ¼ 352 (9.1%)
Placebo: 6 deaths/n ¼ 164 (3.7%)
Within 100 days of randomization (p ¼ 0.02)
PROMISE (Supplemental Ref. 2) Milrinone 1991 1,088 LVEF #35%,
NYHA functional class III–IV
Milrinone: 168 deaths/n ¼ 561 (30%)
Placebo: 127 deaths/n ¼ 527 (24%)
Log-rank test: 28% increase mortality; 95% CI: 1%–61%;
p ¼ 0.038
PROFILE (Supplemental Ref. 3) Flosequinan 1993 2,345 LVEF #35%,
NYHA functional class III–IV
Flosequinan: 255 deaths/n ¼ 1,170
Placebo: 192 deaths/n ¼ 1,175
HR: 1.39; 95% CI: 1.15–1.67; p ¼ 0.0006
PICO (Supplemental Ref. 4) Pimobendan 1996 317 LVEF #45%,
NYHA functional class II–III
Pimobendan (2.5 mg): 13 deaths/n ¼ 106;
HR: 1.5; 95% CI: 0.9–2.5
Pimobendan (5.0 mg): 11 deaths/n ¼ 103
HR: 1.2; 95% CI: 0.7–2.1
Placebo: 6 deaths/n ¼ 108
PRIME II (Supplemental Ref. 5) Ibopamine 1997 1,906 LVEF <35%,
NYHA functional class III–IV
Ibopamine: 232 deaths/n ¼ 953 (25%)
Placebo: 193 deaths/n ¼ 953 (20%)
Relative risk: 1.26; 95% CI: 1.04–1.53; p ¼ 0.017
VEST (Supplemental Ref. 6) Vesnarinone 1998 3,833 LVEF #30,
NYHA functional class III–IV
Vesnarinone (60 mg): 292 deaths/n ¼ 1,275 (22.9%)
p ¼ 0.02 vs. placebo
Vesnarinone (30 mg): 268 deaths/n ¼ 1,275 (21.0%)
p ¼ 0.21 vs. placebo
Placebo: 242 deaths/n ¼ 1,283 (18.9%)
Enoximone Multicenter Trial
(Supplemental Ref. 7)
Enoximone 1990 102 LVEF #40%,
NYHA functional class II–III
Enoximone: 10 deaths/n ¼ 50
Placebo: 3 deaths/n ¼ 52
p < 0.05
EMOTE Trial (Supplemental
Ref. 8)
Enoximone 2007 201 LVEF #25%, NYHA functional class IV,
inotrope dependence
Enoximone: 38 deaths/n ¼ 101
Placebo: 31 deaths/n ¼ 100
p ¼ 0.37
ESSENTIAL Trials Program
(Supplemental Ref. 9)
Enoximone 2009 1,854 LVEF #35%,
NYHA functional class III–IV (2 trials)
Enoximone: 196 deaths/n ¼ 926 (21.2%)
Placebo: 203 deaths/n ¼ 928 (21.9%)
HR: 0.97; 95% CI: 0.80–1.17; p ¼ 0.73 (Note: No
improvement in major clinical outcomes)
CI ¼ confidence interval; EMOTE ¼ EnoxiMone in intravenous inOTropE-dependent subjects; ESSENTIAL ¼ Studies of Oral Enoximone Therapy in Advanced HF; HR ¼ hazard ratio; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association; PICO ¼ Pimobendan in Congestive Heart Failure; PRIME ¼ Prospective Randomised Study of Ibopamine on Mortality and Efficacy;
PROFILE ¼ Prospective Randomized Flosequinan Longevity Evaluation; PROMISE ¼ Prospective Randomized Milrinone Survival Evaluation; VEST ¼ Vesnarinone Trial.
J A C C : H E A R T F A I L U R E V O L . 8 , N O . 4 , 2 0 2 0 Teerlink et al.
A P R I L 2 0 2 0 : 3 2 9 – 4 0 Rationale and Design of GALACTIC-HF
331in cardiac function and most also had confounding
vasoactive or electrophysiologic properties. A recent
proposal classifies these drugs that increase myocar-
dial force production by altering the concentration of
intracellular Ca2þ as calcitropes (3).
Beta-adrenergic agonists increase cardiac contrac-
tility by stimulating the beta-adrenergic receptor,
resulting in generation of cAMP. As a second
messenger, cAMP promotes phosphorylation of
L-type calcium channels to increase calcium influx as
well as ryanodine receptor–mediated sarcoplasmic
reticulum calcium release. These agents also increase
heart rate and may have mild vasodilatory actions.
Xamoterol, a b1-selective partial adrenergic agonist,
increased mortality within 100 days of randomization
in a study of 516 patients with chronic HF. Ibopamine,
a dopamine-1, dopamine-2, and alpha-adrenergic re-
ceptor agonist with mild beta-1 and beta-2 adrenergic
agonist activity demonstrated a 26% excess of deaths
in patients with HFrEF. Phosphodiesterase-3 in-
hibitors increase cardiac contractility by reducing the
degradation of cAMP, resulting in prolonged and
increased signaling with significant increases inintracellular calcium. These agents are also potent
vasodilators. All of the oral phosphodiesterase-3 in-
hibitor drugs, including milrinone, pimobendan, and
enoximone, have demonstrated signals of increased
mortality in chronic HF outcome studies. The largest
of these trials investigated the role of 2 doses of the
phosphodiesterase-3 inhibitor vesnarinone compared
with placebo in 3,833 patients with symptomatic HF
and left ventricular ejection fraction (LVEF) #30%.
There were significantly more deaths in the 60-mg
vesnarinone group (292 deaths, or 22.9%) than in
the placebo group (242 deaths, or 18.9%) (p ¼ 0.02).
Another calcium-based mechanism for increasing
cardiac contractility is to reduce Naþ/Ca2þ exchange,
thereby increasing intracellular calcium, and it is a
putative mechanism of action of flosequinan, which
also has marked vasodilating activity. Despite symp-
tomatic improvements, flosequinan-treated patients
had increases in heart rate and norepinephrine
plasma concentrations, and the PROFILE (Prospective
Randomized Flosequinan Longevity Evaluation) trial
was terminated due to a 39% increase in mortality. Of
note, the excess mortality signal was readily evident
CENTRAL ILLUSTRATION Mechanism of Action of Omecamtiv Mecarbil
Teerlink, J.R. et al. J Am Coll Cardiol HF. 2020;8(4):329–40.
Omecamtiv mecarbil (OM) stabilizes the pre-powerstroke state of myosin enabling more myosin heads to undergo a powerstroke during systole. (A) During diastole,
myosin exists in an equilibrium between an adenosine triphosphate (ATP) state (1) and an adenosine diphosphate (ADP)-Pi state (2); the forward and backward arrows
between (1) and (2), denoting the forward and backward transition rates of ATP hydrolysis, are usually of roughly equal length. State (2) is the “pre-powerstroke” state
and capable of binding to actin. During systole, a subset of myosin heads (10% to 15%) in the pre-powerstroke conformation engage binding sites on actin (3), release
Pi, and undergo a powerstroke to generate force (4), shortening the sarcomere. The loss of ADP (5) and subsequent binding of ATP releases the myosin from the
actin filament. The duration of systole is long enough, in general, for myosin to undergo this cycle only once. OM binds with highest affinity to the pre-powerstroke
state (2) by more than 6-fold compared with the other states, stabilizing the myosin head in that conformation and shifting the equilibrium in diastole toward state (2)
by reducing the transition rate back to state (1) (shorter red arrow). With more myosin heads in state (2), the number of myosin heads ready to bind to the actin
filaments and undergo a powerstroke also increases (thicker green arrow), thus producing more force during each cycle of cardiac contraction. A simple analogy is
that there are multiple hands available to pull on a rope; the more hands (the myosin heads) that can grasp the rope (the actin filament) to pull, the more force is
produced during each contractile cycle. This principle is illustrated in B and C. OM ¼ omecamtiv mecarbil; ADP ¼ adenosine diphosphate; ATP ¼ adenosine
triphosphate.
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TABLE 2 Selected Clinical Studies With Omecamtiv Mecarbil
Trial (Phase), Year(s)
(Ref. #) Subjects Dose (Route) Design Endpoints Major Outcomes
NCT01380223 (I),
2005–2006 (10)
Young, healthy, 85% white,
male subjects in 4
successive cohorts of 8
(n ¼ 34)
0.005–1.0 mg/kg/h
for 6 h (IV)
Double-blind, placebo-
controlled, dose-
escalating, crossover,
single-center trial
1. Maximum infusion dose
tolerated in $8 subjects
for 6 h.
2. Safety, tolerability,
pharmacokinetics,
pharmacodynamics.
1. Maximum tolerated infusion
0.5 mg/kg/h.
2. Dose-dependent linear increase
in SET (r2 ¼ 0.99), with
increased LVEF, FS, and SV.
t1/2 ¼ 17.1–21.0 h. Cardiac
ischemia in some participants
at plasma concentrations
>1,200 ng/ml.
NCT00624442 (II),
2007–2009 (11)
Stable HF, 87% male, 64%
ischemic, HFrEF,
LVEF #40% or
LVEF #30% in cohort 4
(n ¼ 45)
Loading 0.125–
1.0 mg/kg/h;
Maintenance
0.0625–0.5
mg/kg/h (IV)
Double-blind, placebo-
controlled, dose-
escalating, crossover,
multicenter
international trial
1. Safety and tolerability for
2, 24, and 72 h.
2. Establish tolerated range of
pharmacologically active
plasma concentrations.
1. Cardiac ischemia at plasma
concentrations >1,300 ng/ml.
2. Dose-dependent increases in
SET, FS, LVEF, SV, and CO;
decreased HR, QTc, LVESV,
LVEDV, and standing SBP and
DBP.
NCT00682565 (II),
2008 (13)
Stable HF, 80% male,
ischemic HFrEF with
LVEF #35% and angina
(n ¼ 94)
Loading 24–48 mg/h
for 2 h, then
maintenance
6–11 mg/h for
18 h (IV)
Double-blind, placebo-
controlled,
randomized,
multicenter study
1. Safety and tolerability
exercise during infusion;
proportion stopping ETT due
to angina at earlier stage
than baseline.
2. Duration of exercise, angina,
ECG changes.
1. Only 1 patient (receiving
placebo) stopped ETT early
due to angina.
2. No statistical difference in time
to angina, exercise duration, or
ischemic ECG changes.
NCT01786512
ATOMIC-AHF (IIb),
2013–2015 (14)
Acute HFrEF, 77% male, 88%
white, 62% ischemic, with
LVEF #40%, dyspnea and
elevated BNP (n ¼ 613)
Loading 7.5–20 mg/h
for 4 h, then
maintenance
1.5–4 mg/h for
44 h (IV)
Double-blind, placebo-
controlled, dose-
escalating,
randomized
international
multicenter trial
1. Dyspnea relief by 7-point
Likert-type scale at 6, 24,
and 48 h without worsening
HF or death.
2. Safety and tolerability,
biomarkers, hospital length
of stay, 30-day morbidity,
and mortality.
1. No benefit for dyspnea relief at
6, 24, or 48 h vs. pooled
placebo; improved dyspnea in
third cohort vs. paired placebo.
2. No benefit for 30-day death or
worsening HF, length of stay,
or NT-proBNP; increased SET
and SBP; decreased HR and
LVESD.
NCT01300013
COSMIC-HF (IIb),
2011–2015 (15)
Expansion phase: stable HF,
83% male, >90% white,
HFrEF with LVEF #40%
and elevated NT-proBNP
(n ¼ 448)
25 mg twice-daily or
PK-guided
titration to 50 mg
twice daily (oral)
Double-blind, placebo-
controlled, dose-
escalating,
randomized,
multicenter,
international trial
1. Pharmacokinetics of
modified release dosing
over 20 weeks.
2. Safety and tolerability,
echocardiographic, and
biomarker changes over
20 weeks.
1. Modified release allowed
titration to 50 mg twice daily
in 60% of patients.
2. Increased SET and SV and
decreased HR, LVESV, LVEDV,
and NT-proBNP; asymptomatic
small increased troponin at
20 weeks: 0.001 ng/ml with
25 mg and 0.006 ng/ml with
25–50 mg twice daily.
Modified with permission from Psotka et al. (1).
BNP ¼ B-type natriuretic peptide; CO ¼ cardiac output; COSMIC-HF ¼ Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure; DBP ¼ diastolic blood pressure;
ECG ¼ electrocardiogram; ETT ¼ exercise tolerance test; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; HR ¼ heart rate; IV ¼ intravenous; LVEDD ¼ left ventricular end diastolic
dimension; LVEDV ¼ left ventricular end diastolic volume; LVESD ¼ left ventricular end systolic dimension; LVESV ¼ left ventricular end systolic volume; NT-proBNP ¼ N-terminal pro–B-type natriuretic
peptide; PK ¼ pharmacokinetic; QTc ¼ corrected QT interval; SBP ¼ systolic blood pressure; SET ¼ systolic ejection time; SV ¼ stroke volume; t1/2 ¼ plasma half-life; other abbreviations as in Table 1.
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333in most of these trials with approximately 400 death
events. Attempts at increasing cardiac contractility
with oral calcitropes have uniformly resulted in sig-
nals of increased mortality at pharmacologically
effective doses. The challenge for these agents is that
their adverse effects, including increased mortality,
are inextricably linked to their mechanism of benefit.
OM, A NOVEL CARDIAC MYOSIN ACTIVATOR
MECHANISM OF ACTION AND PRECLINICAL STUDIES. OM
was developed to address the hypothesis that direct
activation of the human sarcomere could augment
cardiac performance without the adverse effects of
conventional inotropic agents. To pursue thishypothesis, a high-throughput screen of approxi-
mately 400,000 small-molecule compounds in a bio-
chemically reconstituted sarcomere was performed
and identified small-molecule activators of cardiac
myosin. An initial lead compound was further opti-
mized for potency, physical properties, and pharma-
cokinetics, culminating in the synthesis of OM (4–6).
OM is a selective cardiac myosin activator that in-
creases cardiac contractility by specifically binding to
myosin at an allosteric site (Central Illustration) that
stabilizes its lever arm in a primed position, resulting
in accumulation of cardiac myosin heads in the
primed pre-powerstroke state prior to onset of cardiac
contraction (7). This has the effect of increasing the
number of “force generators” (myosin heads) that can
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334bind to the actin filament and undergo a powerstroke
once the cardiac cycle starts. By stabilizing the pre-
powerstroke state, OM also decreases the turnover
of adenosine triphosphate (ATP) in the absence of an
interaction with the actin filament, potentially
increasing the overall energetic efficiency of the sys-
tem by diminishing ATP use not associated with me-
chanical work. OM increases the contraction of
isolated cardiomyocytes by direct action on the
myofilament, as a myotrope (3), in the absence of
changes in the cardiomyocyte calcium transient (4,8).
The lack of change in the calcium transient differen-
tiates OM from the mechanism of current calcitropes
such as b-adrenergic receptor agonists or phospho-
diesterase inhibitors.
In preclinical models, OM produced dose- and
concentration-dependent increases in cardiac func-
tion as assessed by echocardiography in both Sprague
Dawley rats and beagle dogs (4). In a conscious dog
model of HF produced through a combination of
myocardial infarction followed by continuous rapid
ventricular pacing, OM increased fractional short-
ening, myocardial wall thickening, systolic ejection
time, stroke volume, and cardiac output measured by
implanted hemodynamic and ultrasonographic sen-
sors. OM decreased heart rate and left atrial pressure
without accompanying changes in mean arterial
pressure or change in pressure with respect to time
(dP/dt). No statistically significant changes in
myocardial blood flow and oxygen consumption were
observed (9).
Altogether, OM increased cardiac performance in
the absence of adverse changes in heart rate, blood
pressure, and myocardial oxygen consumption in
preclinical studies at clinically relevant concentra-
tions, supporting its advancement into clinical
studies.
PHASE 1 AND PHASE 2 CLINICAL EXPERIENCE. Prior
to the initiation of the GALACTIC-HF trial, OM was
administered to more than 1,000 participants in 16
completed clinical studies (Table 2). The overall
objective of the phase 1 and phase 2 development
program was to carefully characterize the safety and
tolerability, pharmacokinetics, and effect on cardiac
function in relation to dose and exposure of OM prior
to the conduct of more sizable trials in patients with
acutely decompensated HF and with chronic HF. The
latter trials served to inform the design of a cardio-
vascular (CV) phase 3 outcomes study, the GALACTIC-
HF trial.
Intravenous OM was initially studied in 34 healthy
young men (10) and subsequently in 45 stable pa-
tients with chronic HF and LVEF #40% (11). In both
studies, OM produced dose-dependent increases insystolic ejection time (SET), fractional shortening,
stroke volume, and LVEF, and decreases in ventric-
ular volumes. A risk of symptomatic myocardial
ischemia was associated with plasma concentrations
>1,200 ng/ml. Additional phase 1 studies defined the
pharmacokinetic profile of orally administered OM
and demonstrated low potential for clinically signifi-
cant drug-drug interactions (10–12).
The safety and tolerability of OM in the presence of
exercise and elevated heart rates were assessed in 95
patients with chronic stable ischemic HFrEF,
LVEF #35%, and exercise-induced angina (Table 2)
(13). After 2 baseline, symptom-limited exercise
treadmill tests (ETTs), patients were later randomized
to blinded 20-h infusions of placebo or OM. On the
repeat ETT performed prior to completion of the
study drug infusion, there was no difference in the
primary endpoint (proportion of patients stopping
the ETT during infusion at a stage earlier than base-
line due to angina) between the groups (only 1 patient
in the placebo group stopped their on-treatment ETT
a stage early due to angina), supporting the safety of
OM in a population prone to inducible ischemia.
The ATOMIC-AHF (Acute Treatment with Ome-
camtiv Mecarbil to Increase Contractility in Acute
Heart Failure) study (Table 2) (14) randomized 606
patients hospitalized for acute HF with LVEF #40%,
dyspnea, and elevated natriuretic peptides in 3
ascending-dose cohorts to 48-h infusions of placebo
or OM. Concentration-dependent increases in SET
and systolic blood pressure, and decreases in heart
rate and left ventricular end-systolic dimensions
were observed. The ATOMIC-AHF trial did not
demonstrate a statistically significant difference in its
primary outcome of improvement in dyspnea at 48 h
in the individual OM treatment groups when
compared with the pooled placebo groups, but a
prespecified sensitivity analysis demonstrated a 41%
relative increase in dyspnea relief with the highest
OM dose compared with its matched placebo group, a
finding supported by a nominally significant dose-
and concentration-dependent effect on dyspnea re-
lief. Plasma troponin concentrations were slightly
higher in OM-treated patients compared with
placebo-treated patients (median difference at 48 h,
0.004 ng/ml) but with no relationship with OM con-
centration (p ¼ 0.95). Adverse events were similar,
with numerically fewer patients on OM than on pla-
cebo developing supraventricular tachycardias (1.0%
vs. 8.0%) or renal failure (11.9% vs. 17.2%) during the
infusions. Thus, ATOMIC-AHF trial provided evi-
dence for the safety and tolerability of OM in an
acutely decompensated HF population and suggested
increased dyspnea relief.
FIGURE 1 Prespecified Efficacy Variables in the COSMIC-HF Study
The COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) study had 6 prespecified efficacy variables: (A) systolic ejection time
(SET), (B) stroke volume, (C) left ventricular end-systolic dimension (LVESD), (D) left ventricular end-diastolic dimension (LVEDD), (E) heart rate, and (F) N-terminal
pro–B-type natriuretic peptide (NT-proBNP). The least-squares mean  SEM changes from baseline at week 20 are shown by treatment group: placebo and omecamtiv
mecarbil (OM) pharmacokinetic-guided dose titration (PK) group. The p values represent comparisons to placebo group using a repeated-measures model. The model
was fitted separately for each variable and included the stratification factor of presence or absence of atrial fibrillation or flutter at randomization, baseline value,
treatment group, visit, and the treatment group by visit interaction. Modified with permission from Teerlink et al. (15).
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Activation to Increase Contractility in Heart Failure)
trial evaluated the role of 20 weeks of OM in patients
with stable HF (15). The expansion phase in the
COSMIC-HF trial enrolled 448 outpatients with
chronic symptomatic HFrEF (New York Heart Asso-
ciation functional class II or III), LVEF #40%, and
elevated natriuretic peptides. Patients were random-
ized 1:1:1 to placebo or 25 mg of oral OM twice daily, oran oral OM pharmacokinetic (PK)-guided dose titra-
tion group (initial 25 mg twice daily dose increased to
50 mg twice daily depending on a trough plasma
concentration of OM after 2 weeks of initial therapy)
for a total duration of 20 weeks. In addition to
achieving its primary objective of demonstrating
stable pharmacokinetics of the selected formulation,
all of the prespecified secondary efficacy endpoints
were significantly improved in the OM PK-guided
FIGURE 2 Schematic of Study Design for the GALACTIC-HF Trial
Overview of study design including summary patient inclusion criteria, randomization stratification variables, and visit schedule for GALACTIC-HF. BID ¼ twice daily;
D ¼ day; ED ¼ emergency department; ER ¼ emergency room; GALACTIC-HF ¼ Global Approach to Lowering Adverse Cardiac outcomes Through Improving
Contractility in Heart Failure; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; PK ¼ pharmacokinetic; PO ¼ orally; Q16W ¼ every 16 weeks; SoC ¼ standard of care; W ¼ week.
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336dose titration group (Figure 1). In a community cohort
study, a shorter left ventricular ejection time was
predictive of incident HF (16), and SET has been
shown to be decreased by 10 to 70 ms in patients with
HF (17). SET is also a pharmacodynamic marker of OM
action, and was significantly increased in the OM PK-
guided dose titration group by 25 ms (95% confidence
interval [CI]: 18 to 32 ms; p < 0.0001), suggesting that
OM shifts patients toward a normal ejection duration.
Improved cardiac function was reflected in the
increased stroke volume and reduced end-systolic
dimensions, while reverse cardiac remodeling was
suggested by a decrease in end-diastolic dimensions.
The improvement in cardiac performance also
appeared to result in reduced ventricular wall stress,
as reflected in the decreased N-terminal pro–B-type
natriuretic peptide (NT-proBNP), and sympathetic
withdrawal, supported by the decreased heart rate.
Treatment with OM for 20 weeks was associated with
asymptomatic increases in median plasma troponin
of 0.006 ng/ml (95% CI: 0 to 0.024 ng/ml) in the PK-
guided dose titration group. In epidemiologic
studies, increased troponin is typically associated
with worsened clinical outcomes; however, for this
therapeutic intervention, the clinical significance of
the increase in troponin remains unclear. In the
COSMIC-HF trial, the increase in troponin occurred in
the context of decreased NT-proBNP, reduced heart
rate and improved ventricular volumes, generally
markers of patient improvement and reduced risk.
There was no correlation of the troponin increases
with peak plasma concentrations of OM and no
asymptomatic troponin elevation events werepositive for myocardial ischemia or infarction after
review by independent adjudicators. This magnitude
of change in troponin is evident during diurnal vari-
ation (18) or after vigorous endurance exercise (19).
Additionally, there are examples of therapeutically
beneficial drugs that can cause unfavorable
biomarker changes (e.g., angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers:
increased creatinine; angiotensin receptor neprilysin
inhibitors: increased microalbuminuria). In the
COSMIC-HF trial, OM had a tolerability and adverse
event profile that was similar to placebo, and there
were no differences in atrial or ventricular arrhyth-
mias, myocardial ischemia, or hypotension. Overall,
the results of the COSMIC-HF trial supported the
progression of OM into a CV outcomes trial to defin-
itively assess the balance of benefit and risk for this
novel therapeutic approach.
THE GALACTIC-HF TRIAL:
STUDY DESIGN AND METHODS
The GALACTIC-HF trial (NCT02929329) (Figure 2) trial
is a multicenter, randomized, double-blind, placebo-
controlled CV outcomes trial to evaluate the efficacy,
safety, and tolerability of OM in patients with chronic
HFrEF. The primary outcome of the trial is the time to
the first occurrence of CV death or an HF event. More
than 8,000 patients receiving standard-of-care back-
ground HF therapy recruited from both the hospital
and outpatient settings were randomized in a 1:1
fashion to OM or placebo. Patients were to receive
study treatment from the time of their randomization
TABLE 3 Selected Inclusion And Exclusion Criteria In The GALACTIC-HF Trial
Key Inclusion Criteria Key Exclusion Criteria
Male or female, $18 to #85 yrs of age
History of chronic HF (defined as requiring treatment for HF for a minimum of
30 days before randomization)
LVEF #35%, per subject’s most recent medical record, within 12 months prior to
screening. The most recent qualifying LVEF must be at least 30 days after any
of the following, if applicable:
1) an event likely to decrease EF (e.g., myocardial infarction, sepsis);
2) an intervention likely to increase EF (e.g., cardiac resynchronization therapy,
coronary revascularization); or
3) the first ever presentation for HF
NYHA functional class II to IV at most recent screening assessment
Managed with HF SoC therapies consistent with regional clinical practice guidelines
according to investigator judgment of subject’s clinical status. Oral SoC therapies
for chronic HF (e.g., beta-blockers, renin-angiotensin-aldosterone system
inhibitors) should be present, if not contraindicated. Subjects enrolled during
either HF hospitalization or early after HF hospitalization discharge can be
reinitiating or titrating oral SoC chronic HF therapies at the same time of
randomization with the goal of achieving optimized therapy on study
Currently hospitalized with primary reason of HF OR 1 of the following events within
1 yr to screening:
1) hospitalization with primary reason of HF;
2) urgent visit to ED with primary reason of HF
BNP level $125 pg/ml or an NT-proBNP level $400 pg/ml at most recent screening
assessment (subjects receiving ARNi must use NT-proBNP assessment; for subjects in
atrial fibrillation/flutter at screening, the cutoff levels are: BNP $375 pg/ml or
NT-proBNP $1,200 pg/ml)
Receiving mechanical hemodynamic support (e.g., intra-aortic balloon pump
counterpulsation), or invasive mechanical ventilation #7 days prior to
randomization
Receiving IV inotropes (e.g., dobutamine, milrinone, levosimendan) or IV va-
sopressors (e.g., epinephrine, norepinephrine, dopamine, or
vasopressin) #3 days prior to randomization
Receiving IV diuretic agents or IV vasodilators, supplemental oxygen therapy,
or noninvasive mechanical ventilation (e.g., BiPAP or CPAP) #12 h prior to
randomization (Note: the use of noninvasive ventilation for sleep disor-
dered breathing is permitted)
Acute coronary syndrome (ST-segment elevation myocardial infarction, non–
ST-segment elevation myocardial infarction, unstable angina), stroke, or
transient ischemic attack, major cardiac surgery or cardiac intervention
(i.e., implantation of cardiac closure devices, cardiac resynchronization
therapy, or catheter ablation), percutaneous coronary intervention, or
valvuloplasty/other cardiac valve repair or implantation within the
3 months prior to randomization
Insertion of other cardiac devices (e.g., implantable cardioverter-defibrillator,
permanent pacemaker, monitoring devices) within 30 days prior to
randomization
Severe uncorrected valvular heart disease, hypertrophic or infiltrative cardio-
myopathy, active myocarditis, constrictive pericarditis, or clinically sig-
nificant congenital heart disease
Untreated severe ventricular arrhythmia (e.g., ventricular tachycardia or ven-
tricular fibrillation)
Routinely scheduled outpatient intravenous infusions for HF (e.g., inotropes,
vasodilators [e.g., nesiritide], diuretics) or routinely scheduled
ultrafiltration
Systolic blood pressure >140 mm Hg or <85 mm Hg, or diastolic blood
pressure >90 mm Hg, or heart rate >110 beats/min, or <50 beats/min at
screening
Estimated glomerular filtration rate <20 ml/min/1.73 m2 or receiving dialysis
at screening
Severe, concomitant non-CV disease that is expected to reduce life expectancy
to <2 yrs
Recipient of any major organ transplant (e.g., lung, liver, heart, bone marrow,
renal) or anticipated to receive chronic mechanical circulatory support or
heart transplantation within 12 months from randomization
Planned to be discharged from the hospital to long term care facility
(e.g., skilled nursing facility) or hospice.
History or evidence of any other clinically significant disorder (including car-
diac arrhythmia), condition or disease (with the exception of those out-
lined previously) that, in the opinion of the investigator or Amgen
physician, if consulted, would pose a risk to subject safety or interfere with
the study evaluation, procedures, or completion
See the Supplemental Appendix for a full listing.
ARNi ¼ angiotensin receptor-neprilysin inhibitor; BiPAP ¼ bilevel positive airway pressure; CPAP ¼ continuous positive airway pressure; CV ¼ cardiovascular; ED ¼ emergency department; GALACTIC-
HF ¼ Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure; SoC ¼ standard of care; other abbreviations as in Tables 1 and 2.
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337until 1,590 CV deaths, the secondary outcome on
which the trial is powered, had occurred.
The GALACTIC-HF trial Executive Committee
(Supplemental Appendix) designed the trial and wrote
the study protocol in collaboration with the clinical
team from Amgen, Cytokinetics, and Servier. The
protocol was approved by the Ethics Review Commit-
tee/Institutional Review Board affiliated with each
center and the trial is being conducted in accordance
with Good Clinical Practice and the Declaration of
Helsinki 2002. All participants provided written
informed consent. The trial is internationally regis-
tered (EU Clinical Trials Register 2016-002299-28).STUDY POPULATION. The inclusion and exclusion
criteria of the GALACTIC-HF trial (summarized in
Table 3; see Supplemental Table 1 for full listing) were
designed to enroll patients with symptomatic HF due
to reduced ejection fraction and at an increased risk
for HF events, including CV death. In addition to
selecting patients most likely to benefit from the
cardiac performance enhancing effects of OM, the
higher expected event rate with lower ejection frac-
tion informed the selection of the upper limit for
ejection fraction of 35%. Increased concentrations of
natriuretic peptides provide objective evidence of HF
and are associated with increased rates of HF
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338hospitalizations and CV death. Given that atrial
fibrillation independently increases natriuretic pep-
tide concentrations and to avoid disproportionate
enrichment of atrial fibrillation in the enrolled pop-
ulation, a higher threshold for natriuretic peptides
was selected for patients in atrial fibrillation. Prior
hospitalization for HF is a recognized risk factor for
rehospitalization, but recent data demonstrate that
visits to emergency departments for HF also confer a
substantial risk for rehospitalization (20).
Predischarge initiation of new therapies improves
medication adherence and clinical outcomes (21–23),
yet clinical trials of chronic HF therapies have tradi-
tionally excluded these patients. One of the goals of
the GALACTIC-HF trial was to establish the safety and
efficacy of OM in these patients. The absence of any
known adverse effects of OM on renal function, serum
potassium, blood pressure, or heart rate suggested that
in-hospital initiation would not interfere with initia-
tion or up-titration of guideline-directed medical
therapies. Thus, the entry criteria were designed to
enable inclusion of a substantial proportion (approxi-
mately 25%) of patients currently hospitalized for HF.
Given the lack of adverse effects on blood pressure,
heart rate, and renal function observed in the phase 2
program, inclusive thresholds were designed for
these parameters. Patients with a systolic blood
pressure of >85 mm Hg were eligible; however, pa-
tients with moderate hypertension defined as systolic
blood pressure of >140 mm Hg or diastolic blood
pressure >90 mm Hg were excluded on the assump-
tion that medical therapy for the patient had not been
optimized. Similarly, patients with a heart rate
>110 beats/min or <50 beats/min at screening were
excluded. With respect to renal function, the
cutoff for estimated glomerular filtration rate
was <20 ml/min/1.73 m2.
STUDY TREATMENT. The formulation of OM admin-
istered in GALACTIC-HF trial was selected on the
basis of the pharmacokinetic and efficacy results from
the COSMIC-HF trial (15). Study drug was supplied as
identical OM tablets or matching placebo, and was
administered twice daily in the morning and evening
under fasted or fed conditions, beginning at 25 mg
twice daily. If a dose was missed, the next dose was
taken without replacement.
To enhance the proportion of patients randomized
to OM achieving plasma concentrations of at
least 200 ng/ml, while avoiding concentrations
>1,000 ng/ml, a guided dose titration strategy was
adopted (Supplemental Appendix). After 2 weeks of
25 mg twice daily, a trough plasma concentration of
OM was measured and at week 4 with the patient andinvestigator blinded to the plasma concentrations
and dispensed dose, the dispensed study drug was
adjusted (25 mg twice daily maintained for plasma
concentration $300 and <1,000 ng/ml; 37.5 mg twice
daily for $200 and <300 ng/ml; 50 mg twice daily
for <200 ng/ml). Another trough plasma concentra-
tion of OM was measured at week 6, and depending
on this plasma concentration, a new study drug sup-
ply was dispensed at week 8. OM levels were then
measured at week 12, week 48, and every 48 weeks
thereafter in a blinded fashion but were not used to
adjust dose. After week 8, visits occurred at weeks 12,
24, 36, and 48, and every 16 weeks thereafter, with
study drug dispensed at each visit. Assessment of
study drug adherence is checked by pill counts at all
study drug dispensation visits and at end of study,
and encouraged at all visits.
STUDY ASSESSMENTS. Screening and randomization. All
subjects signed informed consent prior to screening
(Supplemental Appendix). OM was supplied as a
modified release formulation requiring an intact pill,
so a “placebo run-in” was done consisting of observed
oral administration of a single placebo pill to ensure
that participants could swallow pills whole without
chewing, crushing or splitting. Central laboratories
were measured to satisfy respective eligibility
criteria. To facilitate enrollment of hospitalized par-
ticipants, patients could qualify for enrollment using
local lab values (including local BNP), but central
values were drawn in all cases. Subjects meeting
eligibility requirements were randomized 1:1 via an
interactive web-based system to OM or placebo in a
double-blind manner, stratified by randomization
setting (inpatient or outpatient) and region. To be
classified as inpatient, patients were randomized and
received their first test dose of study drug prior to
hospital discharge.
Events and endpo ints . At every visit, adverse
events and study endpoints were assessed. All
deaths, HF events, major cardiac ischemic events
(myocardial infarction or unstable angina hospitali-
zation, and coronary revascularization), and strokes
are adjudicated by an independent external Clinical
Events Committee (Duke Clinical Research Institute)
using standardized definitions (Supplemental
Appendix) (24).
The primary outcome of the trial is the time to the
first occurrence of CV death or an HF event. Given the
importance of CV mortality, the sample size was cho-
sen to power the GALACTIC-HF trial for CV death,
which was also the first secondary endpoint in a hier-
archical testing procedure (Supplemental Appendix,
Supplemental Table 2). An HF event was defined as an
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339urgent, unscheduled clinic, office, or emergency
department visit or hospital admission with a primary
diagnosis of HF in which the patient exhibited new or
worsening symptoms of HF on presentation, had
objective evidence of new or worsening HF, and
received initiation or intensification of treatment
specifically for HF. This definition is consistent with
recent standardized regulatory guidance (24) and ac-
counts for the evolving treatment patterns for
decompensated HF. A recent study has shown that the
risk of death was similar in patients with outpatient
intensification ofHF therapy (hazard ratio: 4.8; 95%CI:
3.9 to 5.9), emergency department visit (hazard ratio:
4.5; 95% CI: 3.0 to 6.7), or hospitalizations (hazard ra-
tio: 5.9; 95% CI: 5.2 to 6.6) for worsening HF (20),
supporting the clinical relevance of these other HF
events.
In the COSMIC-HF study, the total symptom score
of the Kansas City Cardiomyopathy Questionnaire at
20 weeks was significantly improved in OM-treated
patients, with the largest differences relative to pla-
cebo observed in the subgroup of moderately to
severely symptomatic patients at baseline, with
trends in improvements in both frequency and
burden of symptoms (25). To evaluate the potential
symptomatic benefit of OM, several validated patient-
reported outcome instruments (Kansas City Cardio-
myopathy Questionnaire, EuroQOL-5 Dimensions
Questionnaire) were administered at day 1, every
12 weeks through week 48, and yearly thereafter.
Subjects were asked to complete these questionnaires
in a quiet place prior to the medical consultation and
other tests and procedures to avoid biasing re-
sponses. Site staff checked the questionnaires for
completeness before the end of the visit. Clinician
Global Rating Severity and NYHA functional class
were also assessed at screening and all study visits.
Laboratory values , e lectrocard iograms , and
rout ine assessments . Specific assessments were
obtained according to the study schedule
(Supplemental Table 3). Electrocardiograms were
performed and read locally at screening, at day 1,
yearly, and at the end of study, except for approxi-
mately 200 sites in the United States with centralized
electrocardiogram equipment. An electrocardiogram
recorded at the screening visit was used to detect
atrial fibrillation or flutter, which required a higher
BNP or NT-proBNP level for eligibility than did sinus
or other rhythms.
STATISTICAL CONSIDERATIONS. Efficacy analyses
will be performed on the full analysis set, which in-
cludes all randomized patients who will be analyzed
according to their randomized treatment groupassignment (intention to treat). To ensure there is no
avoidable increased risk for harm to patients, accu-
mulating data are formally reviewed quarterly for the
first year and at least every 6 months thereafter by a
Data Monitoring Committee comprising independent,
external experts in HF and clinical trials supported by
an independent statistical group.
In ter im analyses . Two interim analyses for review
by the Data Monitoring Committee were specified at
approximately one-third and two-thirds of the target
1,590 CV deaths. The first interim analysis for futility
alone was completed in March 2019 based on 534 CV
deaths. The Data Monitoring Committee recommen-
dation was to continue the trial without modification.
The second interim analysis will assess for both futility
and superiority, using a 1-sided alpha of 0.0005 (Hay-
bittle-Peto approach) for superiority. The Data Moni-
toring Committee may recommend stopping the trial
for superiority if the primary composite endpoint and
the secondary endpoint of time to CV death both reach
statistical significance. The remainder of the second-
ary endpoints will be assessed with an overall 1-sided
alpha of 0.0005 following the testing diagram if the
study is stopped early (Supplemental Appendix).
Sample s i ze cons iderat ions . The study is
endpoint-driven and will end after accumulation of
approximately 1,590 CV deaths. A sample size of
8,000 patients was chosen to provide 90% power to
detect a hazard ratio of 0.8 for CV death assuming the
following: an annualized rate of CV death of 10% in
the first year and 7% thereafter; a 24-month enroll-
ment period; total study duration set to 48 months; a
3-month treatment lag with a treatment effect hazard
ratio of 0.8 thereafter; 10% annual rate of study drug
discontinuation; and 10% of subjects lost to endpoint
determination either through non-CV death or study
discontinuation over the course of the trial. The
overall type I error is 0.05 for 2-sided testing.
Assuming the rates for experiencing either an HF
event or CV death are double those for CV death alone
and the same other assumptions as for CV death
alone, the primary composite endpoint is expected to
have >99% power. The statistical analysis plan was
approved prior to enrollment of the first patient and
was developed with a special protocol assessment
agreement with the Food and Drug Administration.
Any changes to the statistical analysis plan will be
finalized prior to the end of the study and treatment
unblinding.
CONCLUSIONS
The GALACTIC-HF trial is the first trial designed to
address the hypothesis that selectively increasing
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340cardiac contractility with the cardiac myosin activator
OM in patients with HFrEF will result in improved
clinical outcomes. The preclinical and clinical data
suggest that OM can improve cardiac function,
decrease ventricular wall stress, reverse ventricular
remodeling, and promote sympathetic withdrawal.
The changes in ventricular volumes and natriuretic
peptides are supportive of a potential survival benefit
of OM (26,27). Thus far, OM has not shown liabilities
that typically limit use of current HF therapies, such
as adverse effects on blood pressure, heart rate, po-
tassium homeostasis, or renal function. If the
GALACTIC-HF trial demonstrates favorable clinical
outcomes in patients receiving OM, patients may beable to benefit from this therapy without interfering
with initiation or up-titration of current guideline-
directed medical therapy. Final results of the
GALACTIC-HF trial should be available in 2021 if the
trial runs to full term.
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